Juventas Therapeutics, Inc. Completes Enrollment of Phase II STOP-HF Study of JVS-100 in Patients With Symptomatic Heart Failure /PRNewswire-USNewswire/ -- Juventas Therapeutics, a privately-held clinical-stage company developing novel therapies for treatment of cardiovascular disease, announced today that the company has completed enrollment of ... (more)
http://www.biospace.com/news_story.aspx?StoryID=313268&full=1
http://www.biospace.com/news_story.aspx?StoryID=313268&full=1
No comments:
Post a Comment